Amgen Abandons Alzheimer's Prevention Study
socalTECH
JULY 15, 2019
According to the three, the study of BACE1 inhibitor CNP520 was discontinued, after they concluded the potential benefit for participants in the studies did not outweigh the risk. The companies said that they identified "worsening in some measures of cognitive function" during the Phase 2/3 studies. alzheimer amgen study phase clinical research biotech biopharma pharmaceuticals
Let's personalize your content